InflaRx (NASDAQ:IFRX) Stock Rating Lowered by Zacks Research

InflaRx (NASDAQ:IFRX) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other analysts have also recently commented on the company. HC Wainwright upped their price target on InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Cantor Fitzgerald boosted their price objective on shares of InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. Finally, Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

InflaRx Stock Down 1.6%

Shares of InflaRx stock opened at $2.42 on Tuesday. The business has a fifty day simple moving average of $1.97 and a 200 day simple moving average of $1.64. The stock has a market cap of $356.63 million, a PE ratio of -4.17 and a beta of 2.48. InflaRx has a 12 month low of $0.80 and a 12 month high of $2.95.

InflaRx (NASDAQ:IFRX) last released its earnings results on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Analysts expect that InflaRx will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Large investors have recently modified their holdings of the business. Montanova Capital LLC raised its position in shares of InflaRx by 189.1% during the second quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock worth $51,372,000 after purchasing an additional 15,000,000 shares during the period. Spruce Street Capital LP bought a new position in shares of InflaRx during the 2nd quarter valued at about $11,988,924,000. ADAR1 Capital Management LLC acquired a new position in shares of InflaRx in the 2nd quarter valued at approximately $6,720,000. Bank of America Corp DE acquired a new position in shares of InflaRx in the 3rd quarter valued at approximately $3,316,000. Finally, Suvretta Capital Management LLC increased its stake in InflaRx by 22.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after purchasing an additional 1,450,000 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.